Free Trial

4D Molecular Therapeutics (FDMT) Competitors

4D Molecular Therapeutics logo
$11.24 -0.03 (-0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$10.94 -0.30 (-2.63%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FDMT vs. STOK, ABCL, IMCR, VCEL, JANX, EWTX, RCUS, HRMY, AUPH, and PAHC

Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Stoke Therapeutics (STOK), AbCellera Biologics (ABCL), Immunocore (IMCR), Vericel (VCEL), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Arcus Biosciences (RCUS), Harmony Biosciences (HRMY), Aurinia Pharmaceuticals (AUPH), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry.

4D Molecular Therapeutics vs. Its Competitors

Stoke Therapeutics (NASDAQ:STOK) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Stoke Therapeutics. MarketBeat recorded 13 mentions for 4D Molecular Therapeutics and 6 mentions for Stoke Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.58 beat Stoke Therapeutics' score of 0.37 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stoke Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
4D Molecular Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Stoke Therapeutics has a net margin of 26.25% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. Stoke Therapeutics' return on equity of 18.32% beat 4D Molecular Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Stoke Therapeutics26.25% 18.32% 15.48%
4D Molecular Therapeutics -594,375.81%-40.15%-36.43%

Stoke Therapeutics has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stoke Therapeutics$36.56M51.98-$88.98M$0.8540.80
4D Molecular Therapeutics$40K13,122.70-$160.87M-$3.53-3.18

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 9.5% of Stoke Therapeutics shares are held by insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Stoke Therapeutics presently has a consensus price target of $30.83, suggesting a potential downside of 11.09%. 4D Molecular Therapeutics has a consensus price target of $29.50, suggesting a potential upside of 162.46%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Stoke Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stoke Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
4D Molecular Therapeutics
2 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.55

Stoke Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.93, indicating that its stock price is 193% more volatile than the S&P 500.

Summary

Stoke Therapeutics beats 4D Molecular Therapeutics on 9 of the 17 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDMT vs. The Competition

Metric4D Molecular TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$526.34M$2.66B$6.17B$10.69B
Dividend YieldN/A57.75%5.72%4.83%
P/E Ratio-3.1823.5929.1427.22
Price / Sales13,122.70777.17580.06129.95
Price / CashN/A171.3937.5161.65
Price / Book1.025.4112.476.59
Net Income-$160.87M$33.06M$3.32B$276.14M
7 Day Performance12.74%1.33%1.87%0.01%
1 Month Performance70.30%10.15%8.40%3.60%
1 Year Performance31.00%-2.20%63.49%32.76%

4D Molecular Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FDMT
4D Molecular Therapeutics
2.91 of 5 stars
$11.24
-0.3%
$29.50
+162.5%
+32.1%$526.34M$40K-3.18120News Coverage
Analyst Forecast
STOK
Stoke Therapeutics
3.0817 of 5 stars
$30.34
+0.5%
$27.43
-9.6%
+166.5%$1.65B$36.56M35.69100
ABCL
AbCellera Biologics
2.5092 of 5 stars
$5.67
+2.5%
$8.00
+41.1%
+104.2%$1.65B$28.83M-10.31500Gap Up
IMCR
Immunocore
2.7008 of 5 stars
$32.35
-0.2%
$56.89
+75.9%
-1.3%$1.63B$310.20M-80.88320News Coverage
Positive News
VCEL
Vericel
3.3967 of 5 stars
$33.49
+5.1%
$60.40
+80.4%
-13.5%$1.61B$237.22M279.11300News Coverage
JANX
Janux Therapeutics
2.6806 of 5 stars
$26.29
-0.8%
$78.31
+197.9%
-46.2%$1.59B$10.59M-14.6130
EWTX
Edgewise Therapeutics
3.1567 of 5 stars
$14.71
-2.6%
$38.83
+164.0%
-56.7%$1.59BN/A-9.4960
RCUS
Arcus Biosciences
2.7526 of 5 stars
$16.64
+14.0%
$26.78
+61.0%
-5.3%$1.55B$258M-5.25500Analyst Forecast
HRMY
Harmony Biosciences
4.8021 of 5 stars
$26.36
-0.7%
$46.11
+74.9%
-26.5%$1.53B$714.73M8.50200Positive News
Analyst Downgrade
AUPH
Aurinia Pharmaceuticals
2.7011 of 5 stars
$11.10
-1.5%
$13.00
+17.1%
+68.4%$1.48B$235.13M25.81300News Coverage
PAHC
Phibro Animal Health
4.0255 of 5 stars
$36.58
+0.5%
$28.40
-22.4%
+68.8%$1.48B$1.30B31.002,475Insider Trade

Related Companies and Tools


This page (NASDAQ:FDMT) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners